#1B AstraZeneca 9M and Q3 2023 Results Conference call and webcast for investors and analysts 9th November 2023#22 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other thingsthe risk of failure or delay in delivery of pipeline or launch of new medicines: the risk of failure to meet regulatory or ethical requirements for medicine development or approval, the risk of failures or delays in the quality or execution of the Group's commercial strategies, the risk of pricing, affordability, access and competitive pressures, the risk of failure to maintain supply of compliant, quality medicines, the risk of illegal trade in the Group's medicines, the impact of reliance on third-party goods and services, the risk of failure in information technology or cybersecurity, the risk of failure of critical processes, the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives, the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce, the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change, the risk of the safety and efficacy of marketed medicines being questioned, the risk of adverse outcome of litigation and/or governmental investigations, intellectual property-related risks to our products, the risk of failure to achieve strategic plans or meet targets or expectations, the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition, the risk of failure in financial control or the occurrence of fraud, the risk of unexpected deterioration in the Group's financial position. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.#33 9M and Q3 2023 Results Conference call agenda CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks, Q&A Pascal Soriot Chief Executive Officer Aradhana Sarin Chief Financial Officer Dave Fredrickson EVP, Oncology Business Ruud Dobber EVP, BioPharmaceuticals Business Marc Dunoyer Chief Executive Officer, Alexion Pascal Soriot Chief Executive Officer Susan Galbraith EVP, Oncology R&D Sharon Barr EVP, BioPharmaceuticals R&D B#4CEO Opening Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER#5Total Revenue | +5% 9M 2022 Strong commercial performance and financial delivery in 9M 2023 +15% Total Revenue Ex-COVID-19 $33.8bn Benefitting from broad-based, diverse sources of revenue 9M 2023 CEO Opening Remarks Vaxzevria/COVID-19 mAbs¹ Total Revenue Core EPS +17% 9M 2022 $5.80 Financial Results 9M 2023 Oncology BioPharmaceuticals Oncology 40% Broad-based, diverse source of Total Revenue Rare Disease 9M 2023 % Total Revenue by therapy area R&I V&I Other 14% 3% 3% CVRM 23% 27% CEO Closing Remarks 9M 2023 % Total Revenue by geography US Emerging Markets Europe 41% 20% All growth rates at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 5 1. COVID-19 mAbs = Evusheld and AZD3152, the antibody currently in development. CER = constant exchange rates; mAb = monoclonal antibody; EPS = earnings per share; CVRM = Cardiovascular, Renal & Metabolism; R&I= Respiratory & Immunology; V&I = Vaccines & Immune Therapies; EROW = Established Rest of World. 2023 guidance updated: Core EPS now expected to increase by a low double-digit to low-teens % Rare Disease 17% EROW 11%#6Double-digit growth across US, EM and EU 9M Total Revenue ex-COVID-19 (USD millions) and Growth vs PY +14% 13,940 Strong growth across regions, therapy areas US +20% Ex-China: +37% China: +6% Emerging Markets +14% CEO Opening Remarks 6,748 Europe +8% 3,726 Financial Results Established Rest of World Oncology +20% 13,458 Strong growth across Oncology, CVRM, R&I and Rare Disease underpinning FY outlook 9M Total Revenue (USD millions) and Growth vs PY ■Oncology +19% BioPharmaceuticals 7,926 CVRM +9% 4,729 Rare Disease R&I +12% 5,793 Rare Disease CEO Closing Remarks 6 All growth rates at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Total Revenue and growth rates by region reflect figures ex-COVID-19 medicines. EM = Emerging Markets; EU = Europe; CER = constant exchange rates; CVRM = Cardiovascular, Renal & Metabolism; R&I = Respiratory & Immunology; V&I = Vaccines & Immune Therapies. (73%) 944 V&I#7Hind CELL THERAPY 26 NOVEL ADCs CEO Opening Remarks AstraZeneca - building the pipeline of the future Delivering sustainable, industry-leading growth 7 ADC = antibody drug conjugate; 10 = immuno-oncology; RNA = ribonucleic acid. DOT GENE THERAPY Financial Results IO BISPECIFICS XX Oncology EPIGENETICS NAN S BioPharmaceuticals OLIGONUCLEOTIDES Rare Disease * T-CELL ENGAGERS RNA THERAPIES CEO Closing Remarks Therapy area leadership, broad pipeline and focused investment to deliver transformative new medicines#8Financial Results Aradhana Sarin CHIEF FINANCIAL OFFICER 3#9Total Revenue 9M 2023 - Reported profit and loss - Product Sales - Alliance Revenue - Collaboration Revenue CEO Opening Remarks Product Sales Gross margin Total operating expense¹ - R&D expense - SG&A expense Other operating income and expense Operating profit Tax rate Reported EPS 9M 2023 $m 33,787 32,466 1,004 317 81.6% (22,101) (7,862) (13,845) 1,233 Financial Results 6,959 17% $3.22 CER change % 5 4 99 (28) +12 pp 6 12 2 >3x >2x >2x Oncology % Total Revenue 100 96 3 1 65 23 41 4 21 BioPharmaceuticals Q3 2023 $m 11,492 11,018 377 97 81.0% (7,513) (2,584) (4,800) 70 1,954 17% $0.89 Rare Disease CER change % 6 5 75 (47) +10 pp 12 (33) 69 (6) Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 9 Absolute values at actual exchange rates; changes at CER. Product Sales Gross margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales. 1. Total operating expense includes distribution, R&D and SG&A expenses. R&D = Research & Development; SG&A = Sales, General & Administrative; EPS = earnings per share; pp = percentage points; CER = constant exchange rates. CEO Closing Remarks % Total Revenue 100 96 3 1 65 22 42 1 17 A#10Total Revenue 9M 2023 - Core profit and loss. - Product Sales - Alliance Revenue - Collaboration Revenue Product Sales Gross margin Total operating expense¹ - R&D expense - SG&A expense Other operating income and expense Operating profit Tax rate CEO Opening Remarks Core EPS 9M 2023 $m 33,787 32,466 1,004 317 82.4% (17,452) (7,353) (9,705) 1,172 11,782 19% Financial Results $5.80 CER change % 5 4 99 (28) +2 pp 7 7 8 >3x 16 17 Oncology % Total Revenue 100 96 3 1 52 22 29 3 35 BioPharmaceuticals Q3 2023 $m 11,492 11,018 377 97 81.4% (5,969) (2,485) (3,355) 70 3,545 19% $1.73 Rare Disease CER change % 6 5 75 (47) +1 pp 5 7 (34) 9 9 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 10 Absolute values at actual exchange rates; changes at CER. Product Sales Gross margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales. 1. Total operating expense includes distribution, R&D and SG&A expenses. R&D = Research & Development; SG&A = Sales, General & Administrative; EPS = earnings per share; pp = percentage points; CER = constant exchange rates. CEO Closing Remarks % Total Revenue 100 96 3 1 52 22 29 1 31 B#11$bn 22.9 Net debt end 2022 $12.7bn Cash Flow, Net Debt and 2023 Financial Guidance Continued EBITDA improvement 8.0 CFO Net Debt bridge 0.8 Capex 3.3 4.5 Deal payments Dividend and receipts(¹) Adjusted EBITDA²- Net Debt/EBITDA: 1.7x CEO Opening Remarks 0.2 Other 23.4 Financial Results Net debt end Sep 2023 $14.0bn Oncology BioPharmaceuticals Rare Disease Total Revenue Updated 2023 Guidance (CER) Mid single-digit % increase (previously low-to-mid single-digit % increase) Total Revenue excluding COVID-19 medicines Low-teens % increase (previously low double-digit % increase) CEO Closing Remarks Core EPS Low double-digit to low-teens % increase (previously high single-digit to low double-digit % increase) Low single digit adverse FX impact on Total Revenue Mid single-digit adverse FX impact on Core EPS³ Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 1.Comprises disposal of intangible assets, movement in profit participation liability, purchase of intangible assets, payment of contingent consideration on business combinations, purchase and disposal of non-current asset investments, payment of Acerta Pharma share purchase liability and acquisitions of subsidiaries, net of cash acquired. 2. Rolling 12m EBITDA adding back the impact of unwind of inventory fair value uplift recognised on acquisition of Alexion of $387m (FY 2022: $3,484m). B 11 AstraZeneca credit ratings: Moody's: short-term rating P-1, long-term rating A2, outlook stable. S&P Global Ratings: short-term rating A-1, long-term rating A, outlook stable. 3. Assuming average September 2023 foreign exchange rates for October to December 2023. EBITDA = earnings before interest, tax, depreciation and amortisation; CFO = net cash inflow from operating activities; CER = constant exchange rates; EPS = earnings per share.#1212 Capital allocation Capital allocation strategy unchanged Reinvestment in the business | Free cashflow post-Capex Maintain a strong investment- grade credit rating CEO Opening Remarks Value- enhancing business development CAPEX = capital expenditure; YTD = year-to-date. Progressive dividend policy Priority remains reinvesting in our business Financial Results ● Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Investments to drive future growth Currently >120 projects in Phase II/III development Investments behind launches in new indications and strengthening leadership in existing therapy areas Continued investments in new technologies and platforms including cell and gene therapies Value accretive deals Continue to leverage partnerships to drive innovation and bring medicines to markets quicker >20 new approvals in major markets YTD#1313 AstraZeneca - AI in Commercial Delivering real-time insights AZBrain claims clinical trials EMR DRIVING FASTER, BETTER DECISION MAKING| harnessing technology to deliver better patient outcomes bbb ( Medical + AZ content CEO Opening Remarks Market access Financial Results Advanced analytics enhance real-time decision making Oncology Optimising identification of at-risk patients Applying Al and deep multimodal data to identify high responders BioPharmaceuticals Addressing unmet needs and personalising engagement Predicting treatment eligible patient presentation in clinic Velcheti, V., Klump, E., Long, A., Pulmonary nodule characteristics and workup rates, 2023. Al = artificial intelligence; EMR = electronic medical record. Viv TTTT Rare Disease E⁰ o o O 0 0 0 CEO Closing Remarks >6m analysed handwritten EMR notes in 24hrs 11 omnichannel engines 000 O O O 2.#14Oncology Dave Fredrickson ONCOLOGY BUSINESS Susan Galbraith ONCOLOGY R & D 50 12#15Total Revenue ($m) 5,000 4,500 4,000 Oncology - 9M and Q3 2023 Total Revenue +20% in 9M 2023 fueled by strong global demand growth 3,500 3,000 2,500 2,000 1,500 1,000 500 0 Q3 2021 Q4 Oncology 9M 2023 $13.5bn, +20% Q1 Q2 I 2022 Q3 Q4 Q1 Q2 2023 Q3 CEO Opening Remarks Tagrisso Imfinzi/Imjudo Calquence Enhertu Lynparza (PS) Lynparza milestones Others ● ● ● ● Financial Results ● Oncology ● BioPharmaceuticals Rare Disease Q3 2023: key dynamics Imfinzi/Imjudo +54%, continued strong global launch momentum Calquence +15%, preferred BTKi across 1L and r/r CLL • Enhertu +86%, penetration in DB03, DB04 and new global launches uptake ex-US CEO Closing Remarks Tagrisso +6%, continued ADAURA and FLAURA global demand growth, short-term impact from anti-corruption campaign in CN Lynparza PS +8%, EU, EROW, EM demand growth slightly offset by 2L OC label restriction, decreased PARPI use in the US New indications: EU, JP (Enhertu DL02), CN (Calquence CLL/SLL) Regulatory update: US (Tagrisso FLAURA2 Priority Review, Imfinzi AEGEAN submission acceptance) All growth rates at CER. 15 CER= constant exchange rates; NRDL = National Reimbursement Drug List; PS = Product Sales; EU = Europe; EROW= Established Rest of World; EM = Emerging Markets; CN = China; 2L = 2nd-line; OC = ovarian cancer; PARPi = poly (ADP-ribose) polymerase inhibitor; BTKi = bruton tyrosine kinase inhibitor; 1L = 1st-line; r/r CLL = relapsed/refractory chronic lymphocytic leukaemia; DB03 = DESTINY-Breast03; DB04 = DESTINY-Breast04; DL02= DESTINY-Lung02; SLL = small lymphocytic lymphoma. Collaboration partners: Daiichi Sankyo (Enhertu), Merck & Co., Inc. (Lynparza).#1616 CEO Opening Remarks Financial Results Oncology - Tagrisso and Calquence Leading value propositions, commercial execution reinforce future growth opportunity ● ● Establishing Tagrisso for every EGFRm patient Best-in-class QD oral regimen, leading benefit/risk profile Stage I-III resectable ADAURA Adjuvant Tagrisso Expand reimbursement Increase referral rates (>80%) and adjuvant treated (>65%) Stage III unresectable LAURA Tagrisso post-CRT Drive EGFRm testing in Stg. Ill unresectable HLR H1 2024 1L metastatic FLAURA Tagrisso Support longer DoT globally (>22 mo) FLAURA2 Tagrisso + CTX Address patients with highest unmet need (L858R, CNS mets) Further extend DoT LCM and combination opportunities reinforce Tagrisso as backbone TKI NeoADAURA | PACIFIC-4 | SAFFRON / SAVANNAH | Dato-DXd combos 60% 50% 40% 30% 20% 10% Oncology BioPharmaceuticals BTKI NBRx share Calquence maintaining BTKi leadership in face of competition m say Rare Disease zanubrutinib Calquence CEO Closing Remarks 0% Jan-23 Feb-23 Mar-23 Apr-23 May-23 Jun-23 Jul-23 Aug-23 Sep-23 Oct-23 ww Whax ibrutinib Sustained 1L CLL leadership, recovery in r/r share Source: Based on internal new to brand prescription (NBRx) analysis by AstraZeneca UK Limited using IQVIA US National Prescription Audit Market Dynamics (NPA MD) for the period of September 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. EGFRM= epidermal growth factor receptor mutated; QD = once daily; 1L = 1st-line; CRT = chemoradiotherapy; SoC = standard-of-care; 10 = immunotherapy; Stg. = stage; OS = overall survival; DoT= duration of therapy; mo. = months; CTX = chemotherapy; CNS = central nervous system; TKI = tyrosine kinase inhibitor; Dato-DXd = datopatomab deruxtecan; BTKI = bruton tyrosine kinase inhibitor; NBRX = new-to-brand prescription; CLL = chronic lymphocytic leukemia; r/r = relapsed refractory.#17Consolidating leading position in EGFRm lung | FLAURA2¹,²2 CEO Opening Remarks FLAURA2 - longest mPFS >29 mo >50% patients with CNS metastases at baseline showed complete response FLAURA-2 patient with CNS LMD showed deep, durable response Baseline MRI First post-baseline Most recent follow-up scan (6 weeks) (25 months) ooo Oncology - R&D highlights Data at WCLC and ESMO reinforce AstraZeneca leadership across tumour types pMMR Financial Results dMMR Expanding into new tumour types in gynae | DUO-E³ First 10+ PARP inhibitor option for 1L advanced endometrial Deeper benefit with Lynparza in pMMR and PD-L1+ subgroups CTX CTX + Imf CTX + Imf + Lyn CTX CTX + Imf CTX + Imf + Lyn Oncology 9.7m 9.9m 7.0m 15.0m BioPharmaceuticals NR 31.8m Rare Disease Dato-DXd beat conventional monotherapy CTX | TL01, TB014,5 PFS Dato-DXd vs CTX CEO Closing Remarks Best-in-class profile supports combination with 10 Broad potential in earlier lines and other tumour types TL01 HR, 0.63 Non-squamous 2L+ NSCLC TB01 HR, 0.63 HR+/HER2- 2L+ mBC *Lesions in the right precentral gyrus ("motor cortex"), patient scans with permission from FLAURA2 investigator. 1. Janne PA et al. Abstract PL03.13 presented at World Conference on Lung Cancer 2023; 2. Janne PA et al. Abstract #LBA68 presented at European Society of Medical Oncology 2023; 3. Westin S et al. Abstract #LBA41 presented at European Society of Medical Oncology 2023; 4. Ahn M et al. Abstract #LBA12 presented at European Society of Medical Oncology 2023; 5. Bardia et al. Abstract #LBA11 presented at European Society of Medical Oncology 2023. WCLC = World Conference on Lung Cancer; ESMO = European Society of Medical Oncology; EGFRm = epidermal growth factor receptor mutation; NSCLC = non-small cell lung cancer; 1L = 1st-line; CNS = central nervous system; CR = complete response; NEJM = New England Journal of Medicine; CTx = chemotherapy; LMD = leptomeningeal disease; MRI = magnetic resonance imaging; gynae = gynaecological; 10 = immunotherapy; PARP = poly (ADP-ribose) polymerase; p/dMRR = 17 proficient / deficient mismatch repair; PD-L1 = programmed death-ligand 1; Imf = Imfinzi; Lyn = Lynparza; NR = not reached; Dato-DXd = datopotamab deruxtecan; combo = combination; mPFS = median progression-free survival; HR = hazard ratio; 2L = 2nd-line; HR+ = hormone-receptor positive; HER2- = human epidermal growth factor receptor 2 negative; mBC = metastatic breast cancer. Collaboration partner: Daiichi Sankyo (Dato-DXd).#18Best change from baseline (%) PD-L1 NE 0 -10 -20 -30 -40 -50 -60 -70 -80 Oncology - R&D highlights Volrustomig leading new wave of immuno-oncology bispecific molecules 1L adv. NSCLC with CTX¹ Encouraging early phase data for volrustomig first-in-class monovalent bispecific molecule targeting PD-1 and CTLA-4 Treatment-naïve adv. RCC patients² PD-L1 <1% CEO Opening Remarks Population (N=50) ITT (n=49) PD-L1<1% (n=36) PD-L1 1-49% PD-L1 >50% >30% reduction in target lesions (%) 49 55.6 ORR (%) 40.8 44.4 Best change from baseline (%) 100 80 60 40 20 0 -40 -60 -80 -100 Financial Results ‒‒‒‒‒ CR PR SD PD NE Oncology ORR: 48.4%, DCR: 90.3% Path CR BioPharmaceuticals t iCCR Rare Disease R Four bispecific Phase III trials announced eVOLVE-Lung02 | 1L mNSCLC PD-L1 < 50% volrustomig + CTx pembro + CTX CEO Closing Remarks volrustomig eVOLVE-Cervical | volrurstomig following ccRT in high risk LA cervical cancer pembro eVOLVE-Meso | volrustomig + CTx then volrustomig in newly diagnosed unresect. malignant pleural mesothelioma 1. Ahn MJ et al. Abstract #LBA56 presented at European Society of Medical Oncology 2022; 2. Voss M et al. Abstract #1883MO presented at European Society of Medical Oncology 2023. PD-(L)1 = programmed cell death (ligand) 1; CTLA-4 = cytotoxic T lymphocyte antigen 4; 1L = 1st-line; adv.= advanced; (m)NSCLC = (metastatic) non-small cell lung cancer; CTx = chemotherapy; NE = not evaluable; ORR = objective response rate; ARTEMIDE-Bil01 | rilvegostomig + CTx in biliary tract cancer after resection with curative intent ITT = intention-to-treat; RCC = clear cell renal carcinoma; DCR = disease control rate; path/icPR = pathologic/immune confirmed complete response; PR = partial response; SD = stable disease; PD = progressive disease; R = randomise; pembro = 18 pembrolizumab; LA = locally advanced; CCRT = concurrent chemoradiotherapy; volrust = volrustomig; observ = observation; nivo = nivolumab; ipi = ipilimumab; 10 = immuno-oncology; ADC = antibody drug conjugate. Collaboration partner: Compugen (rilvegostomig). Rapidly advancing 10 bispecific programmes into Phase III with potential to combine with ADCs#1987H4 EGFR Oncology - R&D highlights Establishing AstraZeneca portfolio of differentiated ADCs FRa CLDN18.2 GPRCSD Five wholly owned ADCs already in the clinic Clinical stage trials ongoing in lung, breast, haematology, GYN/GU and GI B7H4 TOP1i CMET TOP1i Fita TOPII CLDN18.2 MMAE GPRC5D MMAE AZD8205 (B7H4) DAR 8 AZD9592 (EGFR/CMET) DAR 6 AZD5335 (FRA) DAR 8 AZD0901 (CLDN18.2) DAR 4 CEO Opening Remarks LM-305 (GPRC5D) DAR 4 PRECLINICAL PHASE I Financial Results PHASE II PHASE III INDICATIONS OF INTEREST Breast, BTC, ovarian, endometrial NSCLC, HNSCC Ovarian, lung Oncology Gastric, GEJ, pancreatic Multiple myeloma Best SOD change from baseline, % BioPharmaceuticals 60 AZD0901 Promising efficacy in gastric / GEJ cancer 40 20 0 -20 -40 -60 -80 -100 Rare Disease 2.2 mg/kg 2.6 mg/kg 3.0 mg/kg A unconfirmed response BoR in gastric / GEJ cancer (IHC 2+, ≥20% TC)¹ Phase I dose escalation / expansion Claudin 18.2- MMAE warhead CEO Closing Remarks BER8999RESS EEEEEEEEE ValCit linker THOM Broader clinical development programme in progress 1. Xu RH et al. Abstract 434420 presented at ASCO Virtual Plenary on 7 November 2023. ADC images for illustrative purposes only; actual drug positions may vary. ADC = antibody drug conjugate; GYN = gynaecological; GU = genitourinary; Gl = gastrointestinal; B7H4 = B7 homolog 4; DAR= drug to antibody ratio; EGFR= epidermal growth factor receptor: CMET =mesenchymal-epithelial transition factor ; FRα = folate receptor alpha; CLDN18.2 = claudin 18.2; CPRC5D = G-protein coupled receptor C family 5D; TOP1i = topoisomerase 1 inhibitor; MMAE = monomethyl auristatin E; BTC = biliary tract cancer; NSCLC = non-small cell lung cancer; HSNCC = head and neck squamous cell 19 carcinoma; GEJ = gastroesophageal junction; BoR = best overall response; IHC = immunohistochemistry; TC = tumour cell; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease; NE = not evaluable. Collaboration partner: Keymed Biosciences (AZD0901).#20CAR copies/ug gDNA 1x106 1x105 1x104 1x10³- Innovative armoured CAR-T programme for solid tumour TGFBRIIDN armouring enhances potential effectiveness CAR-T in solid tumours 1x10² 1x10¹ 1x10⁰ 1x10-1 Oncology - R&D highlights In-house development and strategic collaborations expand our reach in cell therapy 0 CAR copies in peripheral blood 20 AZD7003 (C-CAR031)¹ | armoured GPC3 40 CEO Opening Remarks -C003 -C005 -C006 60 80 100 Time post infusion (days) AZD0754 armoured STEAP2 120 Financial Results -C007 -C008 - C009 140 Oncology 160 Encouraging FIH data in HCC Strong expansion and persistence of CAR-T cellular kinetics Promising anti-tumour activity, objective responses in several patients BioPharmaceuticals AZD6422 | armoured Claudin 18.2 NT-125 multispecific Rare Disease Advancing T-cell receptor therapies acquired from Neogene NT-175 monospecific armoured NT-112 monospecific armoured PRECLINICAL PHASE I CEO Closing Remarks cellectis EDITING LIFE PHASE II PHASE III Collaboration announced Νον 2023 1. Designed by AstraZeneca and manufactured and developed in China by Cellular Biomedicine group. CAR(-T) = chimeric antigen receptor(-T cell); TGFBRIIDN = dominant negative transforming growth factor ß receptor II; GPC3 = Glypican 3; FIH = first-in-human; HCC = hepatocellular carcinoma; STEAP2 = human 6-transmembrane epithelial antigen 20 of prostate 2; IND = investigational new drug. Acquisition of Neogene Therapeutics was completed on 16 January 2023, Neogene Therapeutics is a global clinical-stage biotechnology company focused on discovery, development and manufacturing of next-generation T-cell receptor therapies. Differentiated allogeneic platform B#21BioPharmaceuticals Ruud Dobber BIOPHARMACEUTICALS BUSINESS Sharon Barr BIOPHARMACEUTICALS R&D O n 00 BAU#22Total Revenue ($m) Q3 dynamics 3,000 2,500 2,000 BioPharmaceuticals - 9M and Q3 2023 CVRM Total Revenue +19% in 9M 2023 and strong launch brand momentum in R&I 1,500 1,000 500 0 Q3 CVRM 9M 2023 $7.9bn, +19% Q4 2021 Q1 Q2 Q3 2022 Q4 Q1 Q2 2023 Farxiga Brilinta Lokelma Others Q3 Farxiga +41%, demand growth outpacing SGLT2i Lokelma, roxadustat both up >30% Total Revenue ($m) 1,800 1,600 1,400 Q3 dynamics 1,200 1,000 800 600 400 200 0 CEO Opening Remarks ● Q3 Q4 2021 Financial Results R&I 9M 2023 $4.7bn, +9% Q1 Q2 Q3 2022 Q4 Q1 Fasenra Breztri Tezspire Saphnelo Symbicort Others Q2 2023 Oncology Q3 Fasenra, +10%, continued uptake of biologics Breztri, +69%, to $171m, global share gains Tezspire, +19% QOQ, strong launches continue Total Revenue ($m) BioPharmaceuticals Q3 dynamics 2,500 2,000 1,500 1,000 500 Rare Disease Q3 Q4 2021 V&I 9M 2023 $944m CEO Closing Remarks Q1 Q2 Q3 Q4 Q1 2022 Q2 Q3 2023 COVID-19 mAbs¹ Beyfortus FluMist Synagis Vaxzevria COVID-19 medicines $nil in Q3 FluMist +23%, new orders and phasing Beyfortus, first commercial sales and milestone All growth rates at CER. 1. COVID-19 mAbs = Evusheld and AZD3152, the antibody currently in development 22 CER = constant exchange rates; CVRM = Cardiovascular, Renal and Metabolism; SGLT2i = sodium-glucose cotransporter 2 inhibitors; R&I= Respiratory and Immunology; QoQ = quarter on quarter; V&I= Vaccine and Immune Therapies; mAbs = monoclonal antibodies. Collaboration partners: Amgen (Tezspire); Sanofi (Beyfortus).#23100% 50% BioPharmaceuticals - 9M and Q3 2023 Portfolio evolution enables long-term sustainable growth 0% Key R&I medicines grew 42% in Q3 2023 % of R&I Total Revenue Q3 2020 ■ Fasenra ■ Breztri !! Q3 2021 Q3 2022 Q3 2023 +42% growth in Q3 Tezspire Symbicort Daliresp ■ Saphnelo ■ Pulmicort ■ Other CEO Opening Remarks Growth of newer brands more than offset generic impact on older medicines Financial Results Tezspire market leadership within first year of launch New-to-brand share¹ in severe uncontrolled asthma Germany Oncology Tezspire Nearest competitor Others BioPharmaceuticals Tezspire market share expansion globally within growing class 60% OLL Japan 40% 100% Farxiga - substantial growth opportunity remains 80% 20% 0% Rare Disease Potential to increase proportion of diagnosed and treated CKD and HF patients 26% CEO Closing Remarks CKD 17% 66% I 17% HF Prevalent Diagnosed Treated to guideline Farxiga growth strengthens foundation for next-gen CVRM 1. Based on internal new to brand prescription (NBRx) analysis by AstraZeneca UK Limited using data from the following sources: IQVIA Japan Rx, and IQVIA Germany LRX, IQVIA PharmaScope® National and IQVIA DKMⓇ data for the period Aug 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. 2. Sources for CKD & HF prevalence: 1Jager KJ, et al; Nephrol Dial Transplant. 2019;34(11):1803-1805. 2Vos T et al. The Lancet. 2017; 390(10100):1211-59. Analysis prepared based on: Germany, France, Italy, Spain, UK and US using AZ internal projections provided by local marketing companies. CKD prevalence and diagnosis based on Stages 2b-4a; treated to guideline is based on total SGLT2i penetration July 2023 IQVIA EMR patient record data US, EU3 and UK; Telomera patient record data for Spain. R&I = respiratory and immunology; LoE = loss of exclusivity; CKD = chronic kidney disease; CVRM = Cardiovascular, Renal and Metabolism; LCM = lifecycle management. Collaboration partners: Amgen (Tezspire). 23#24Hypertension ~120m Chronic Kidney Disease ~35.5m Heart Failure ~6.5m Farxiga BioPharmaceuticals - R&D highlights Advancing potential novel medicines to address unmet needs across CKD and HF Farxiga Uncontrolled Hypertension ¹ CEO Opening Remarks ~37m baxdrostat ~7m baxdrostat/dapagliflozin ~20m balcinerone/ dapagliflozin ~12m² Financial Results Farxiga FDC lifecycle management monotherapy Oncology Resistant Hypertension¹ High proteinuria ~12m BioPharmaceuticals zibotentan/dapagliflozin ~4m³ Rare Disease 4 CEO Closing Remarks potential new medicines tailored approach to address biological mechanisms driving disease progression Phase III initiated zibo/dapa in CKD with high proteinuria Phase III initiation planned before YE, baxdrostat in HTN Broad disease epidemiology figures are based on US prevalent patients as per CDC. 1. Simone Romano et al. Internal and Emergency Medicine, 02 August 2023. Hypertension, uncontrolled hypertension and resistant hypertension: prevalence, comorbidities and prescribed medications in 228,406 adults resident in urban areas. 2. Jens van de Wouw et al. Front. Physiol., 04 September 2019 Sec. Clinical and Translational Physiology Volume 10-2019. 3. CKD in the General Population, NIDDK. 4. 24 CKD Prevalence by hypertension status and year, NHANES, ~25-30% of adults diagnosed with hypertension have CKD. 1 dapagliflozin = Farxiga; m = millions; CKD = chronic kidney disease; HF = heart failure; HTN = hypertension#25Percentage mean change in UACR from baseline to week 12 BioPharmaceuticals - R&D highlights Data at ASN and ERS publication support Phase III trials 0% -10% -20% -30% -40% -50% -60% zibotentan / dapagliflozin Chronic Kidney Disease with high proteinuria Phase II ZENITH: UACR reduction UACR >30mg/g signals presence of urine albumin, marker for CKD zibo/dapa (1.5/10mg) zibo/dapa (0.25/10mg) CEO Opening Remarks -53% -48% zibo/dapa demonstrated clinically meaningful reduction in UACR across both doses dapa (10mg) -28% SOCIETY Phase III trial initiated, opportunity to increase patient benefit with synergistic combination treatment OF LOGI Financial Results ១០ Oncology RAGE/EGFR pathway (IL-33⁰x) preventing epithelial dysfunction COPD Severe viral LRTD Asthma, COPD tozorakimab | IL-33 mAb BioPharmaceuticals EGFR Y OBERON, TITANIA, MIRANDA Rare Disease TILIA FRONTIER-3, FRONTIER-4 (Phase II) CEO Closing Remarks ST2 pathway (IL-33red) preventing airway inflammation >2024 >2024 UPCOMING 1. Based on KDIGO guidelines; high proteinuria defined as UACR >300m/g. 2. Global Burden of Disease Study 2019, Lower Respiratory Infection collaborators 3. ACCORD-2 is a University of Southampton trial that investigated potential treatments for patients hospitalised with COVID-19 during the pandemic 4. Odds ratio adjusted for age and baseline COVID-19 severity. 5. IL-33/SST2 complex biomarker defined as patients with 230.15U/mL. 25 ASN = American Society of Nephrology; ERS = European Respiratory Society; CKD = chronic kidney disease; UACR = urine albumin-to-creatinine ratio; zibo = zibotentan; dapa = dapagliflozin (Farxiga); SoC = standard-of-care; IL-33 = interleukin-33; SST2 = soluble suppression of tumorigenesis-2; LRTD = lower respiratory tract disease. Dual pathway inhibition could provide a unique opportunity in inflammatory diseases#26ECC5004 (GLP-1RA) global development and commercialisation rights ¹ Potential for no titration High bioavailability, favourable tolerability profile Novel once-daily oral small molecule Efficacy at low doses - 10 to 30mg CEO Opening Remarks Phase II planned 2024 BioPharmaceuticals Accelerating presence in obesity with ECC5004, a novel once-daily oral GLP-1RA Financial Results Significant market opportunity in obesity Farxiga ¡ on-market O O O O O Oncology Diabetes, dyslipidemia, hypertension, HF, renal disease, NASH 1bn people living with obesity Obesity is driver for >200 chronic diseases O AZD6234 LA Amylin Phase I O BioPharmaceuticals baxdrostat ASI Phase III O O O Opportunity beyond obesity to address cardiometabolic disease Rare Disease O mitiperstat MPO Phase II O O O OOO AZD5462 ORXFP1 CEO Closing Remarks Phase I ECCOGENE 诚益生物 26 1. In China, Eccogene and AstraZeneca will operate under co-development and co-commercialisation agreement. GLP-1RA = glucagon-like peptide 1 receptor agonist; HF = heart failure; NASH = non-alcoholic steatohepatitis; LA = long-acting; ASI = aldosterone synthase inhibitor; MPO = myeloperoxidase; ORXFP1 = oral relaxin family peptide receptor 1; oPCSK9 - oral proprotein convertase subtilisin/kexin type-9. AZD0780 OPCSK9 Phase I Strong track record in cardio renal metabolic diseases, opportunity for monotherapy and combinations to address broad range of co-morbid diseases#27Rare Disease Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION 3#28Total Revenue ($m) Q3 dynamics Total Revenue by medicine 9M 2023 $5.8bn, +12% 2,000 1,800 1,600 1,400 1,200 1,000 800 600 400 200 0 Q3² Q4 Q1 Q2 Q3 Q4 Q1 Rare Disease - 9M and Q3 2023 Strong double-digit growth in 9M 2023 with Total Revenue +12%, momentum into year-end 2021 2022 Q2 2023 Ultomiris Soliris Strensiq Others¹ Q3. Ultomiris +49%, neurology demand, new market access; Soliris (12%), successful conversion Strensiq +21%, and Koselugo +81%, new patient demand Total Revenue ($m) CEO Opening Remarks Q3 dynamics 2,000 1,800 1,600 1,400 1,200 1,000 800 600 400 200 0 Financial Results Total Revenue by region Q3 Oncology Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2021 US Europe EROW Emerging Markets 2022 2023 US +9% and EU +8%, neurology demand EROW +22%, neurology demand, expanded access Emerging Markets +70%, demand growth, expanded access BioPharmaceuticals Key dynamics Rare Disease Ultra-rare diseases (PNH, aHUS) C5 franchise indications CEO Closing Remarks US All growth rates at CER. 1. Includes Kanuma and Koselugo. 2. Q3 2021 Total Revenue reported only comprise of those booked by AstraZeneca following completion of the acquisition of Alexion on 21 July 2021. EU = Europe; EROW= Established Rest of World; C5 = C5 inhibitors Ultomiris and Soliris; NMOSD = neuromyelitis optica spectrum disorder; gMG = generalised myasthenia gravis; PNH = paroxysmal nocturnal hemoglobinuria; aHUS = 28 atypical hemolytic uremic syndrome; CER = constant exchange rates. Collaboration partners: Merck & Co., Inc. (Koselugo). Neurology (gMG, NMOSD) Neurology growing proportion of C5 franchise Smaller proportion from ultra rare disease, PNH and aHUS#29Rare Disease - R&D highlights Advancing expansion of Ultomiris in nephrology Mean spot UPCR 24-hr (g/g) Mean ± SE for spot UPCR (g/g) 2.50 2.25 2.00 1.75 1.50 1.25 1.00 0.75 0.50 2 T BL 2 4 Ultomiris Phase II SANCTUARY trial in IgAN CEO Opening Remarks over 26 WEEKS T 10 14 Time (weeks) 18 Ultomiris placebo 22 26 Financial Results 1 rapid, complete and sustained complement inhibition at week 4 BASN American Society of Nephrology with key endpoints met: >40% reduction in proteinuria stable eGFR Oncology Potential disease-modifying reduction in proteinuria IgAN (diagnosed): BioPharmaceuticals Rare Disease Data supports initiation of potential Phase III trial IgAN | Abnormal IgA protein accumulates in kidneys, activating complement cascade US >100k CEO Closing Remarks Complement system plays a clear role in the pathogenesis of IgAN EU5 >100k k > TATL 29 mAb = monoclonal antibody; IgAN = immunoglobulin A neuropathy; UPCR = urine protein creatinine ratio; SE = standard error; eGFR = estimated glomerular filtration rate; IgA = immunoglobulin A; EU5 = France, Germany, Italy, Spain, United Kingdom; CN = China; RAASI = renin-angiotensin-aldosterone system inhibitors. CN >300k significant unmet need for patients optimised on RAASI#30CEO Closing Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER#31B AstraZeneca BUILDING A PIPELINE OF THE FUTURE XX Hind 26 CEO Opening Remarks AstraZeneca Focused investment in pipeline of the future, rich near-term Phase III catalyst flow NAN Financial Results Y Oncology LAURA DESTINY-Breast06 Near-term rich catalyst flow through 2024 anselamimab (CAEL-101) BioPharmaceuticals TROPION-Breast02 WAYPOINT Rare Disease EGFRM NSCLC (unresectable Stg. III) HER2-low breast cancer (2L) AL amyloidosis TNBC (locally rec. inop./met.) CRSWNP Confident in delivering on our ambition for industry-leading growth CEO Closing Remarks 31 EGFRM= epidermal growth factor receptor mutation; NSCLC = non-small cell lung cancer; Stg. = Stage; HER2 = human epidermal growth factor receptor 2; 2L = 2nd-line; AL = light chain; TNBC = triple negative breast cancer; rec. = recurrent; innop. = inoperable; met. = mestastatic; CRSwNP = chronic rhinosinusitis with nasal polyps. H1 2024 H1 2024 H2 2024 H2 2024 H2 2024#3232 Question & Answer Session Pascal Soriot EXECUTIVE DIRECTOR & CHIEF EXECUTIVE OFFICER Susan Galbraith EXECUTIVE VICE PRESIDENT, ONCOLOGY R&D Ruud Dobber EXECUTIVE VICE PRESIDENT, BIOPHARMACEUTICALS BUSINESS Aradhana Sarin EXECUTIVE DIRECTOR & CHIEF FINANCIAL OFFICER Dave Fredrickson EXECUTIVE VICE PRESIDENT, ONCOLOGY BUSINESS Iskra Reic EXECUTIVE VICE PRESIDENT, VACCINES AND IMMUNE THERAPIES Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION Sharon Barr EXECUTIVE VICE PRESIDENT, BIOPHARMACEUTICALS R&D Leon Wang EXECUTIVE VICE PRESIDENT, INTERNATIONAL B#33Appendix ■ ■ ■ ■ Pipeline Highlights Oncology tumour maps Emerging Markets performance Key medicines performance by therapy area B#34Delivering on science-led innovation Selected key pipeline highlights since Q2 2023 Results 3 Breakthrough Designations (US): Tagrisso EGFRM NSCLC (1st-line) (FLAURA2) Enhertu HER2-overexpressing advanced or metastatic colorectal cancer (DESTINY-CRC02) Enhertu HER2-expressing tumours (DESTINY- PanTumour02) 6 regulatory approvals in major markets, including: Lynparza (JP) prostate cancer (1st-line) (PROpel) Enhertu (EU, JP) HER2m NSCLC (2nd-line+) (DESTINY-Lung02) Calquence (CN) CLL (ASCEND) APPENDIX | Pipeline Highlights Oncology BioPharmaceuticals Rare Disease Forxiga (CN) HFPEF (DELIVER) Soliris (CN) neuromyelitis optica spectrum disorder 34 EGFRM= epidermal growth factor receptor-mutated; HER2 = human epidermal growth factor receptor 2; HER2m = human epidermal growth factor receptor 2-mutated; NSCLC = non-small cell lung cancer; CLL = chronic lymphocytic leukaemia; HFpEF = heart failure with preserved ejection fraction. Collaboration partners: Daiichi Sankyo (Enhertu), Merck & Co., Inc. (Lynparza).#35AstraZeneca in Lung Cancer Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030 Est. epi (G7) IO sensitive c.70% EGFRm c.16% Other tumour drivers c.12% HER2m c.2% established SoC resectable Stg. I-III ~200K Imfinzi AEGEAN volrustomig + CTx NEOCOAST-2 Tagrisso ADAURA Tagrisso neoADAURA unresectable Stg. 1-11 ~30K Imfinzi w/SBRT PACIFIC-4 Stg. III ~70K CRT → Imfinzi PACIFIC CRT + Imfinzi PACIFIC-2 Imfinzi combos PACIFIC-8, -9 improvements across PD-L1 spectrum CRT → Tagrisso LAURA CRT Imfinzi PACIFIC 1L ~350K Imfinzi + Imjudo + CTx POSEIDON Dato-DXd + 10 TROPION-Lung08/TROPION-Lung07/AVANZAR Enhertu + 10 + CTX DESTINY-Lung03 volrustomig + CTx eVOLVE-Lung02 rilvegostomig (PD1/TIGIT) ARTEMIDE-1 Tagrisso FLAURA Tagrisso + CTx FLAURA2 metastatic Enhertu DESTINY-Lung04 2L+ ~290K Imfinzi + ceralasertib LATIFY Dato-DXd TROPION-Lung01 AZD9592 (EGFR/CMET ADC) EGRET sabestomig (PD1/TIM3) savolitinib + Tagrisso SAFFRON/SAVANNAH AZD9592 (EGFR/CMET ADC) EGRET Dato-DXd TROPION-Lung01 TROPION-Lung05 APPENDIX | Oncology tumour maps Enhertu DESTINY-Lung02 Leading the future of lung cancer treatment Establishing Tagrisso as backbone TKI in EGFRm Imfinzi leading 10 in unresectable Advancing best-in-class ADCs to replace systemic chemotherapy Delivering next-wave bispecifics to improve on PD1/PD-L1 Developing novel combinations, including 10 + ADCs Investing behind new technologies and platforms, including cell therapy and testing/screening Est epi (G7) = estimated epidemiology across G7 (US, EU5, JP); Stg. = stage; CTx = chemotherapy; SBRT = stereotactic body radiation therapy; CRT = chemoradiotherapy; pembro = pembrolizumab; 10 = immunotherapy; ADC = antibody-drug conjugate; PD1 = programmed cell death protein 1; EGFR = epidermal growth factor receptor; c-MET = mesenchymal-epithelial transition factor; TIGIT = T-cell immunoreceptor with immunoglobulin and ITIM domains; 35 CTLA4 = cytotoxic T-lymphocyte associated protein 4; TIM3 = T-cell immunoglobulin and mucin domain-containing protein 3; SoC = standard of care; TKI = tyrosine kinase inhibitor; HER2m = human epidermal growth factor receptor 2 mutated. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Compugen (rilvegostomig). B#36AstraZeneca in Breast Cancer Ambition to eliminate breast cancer as a cause of death established SoC Est. epi (G7) HER2-positive 15-20% HR-positive 65-75% HER2-low 1+, 2+ 60% TNBC 10-15% HER2-low 1+, 2+ 35% gBRCAm 5% of HR-positive 15% of TNBC Neoadjuvant 540k Enhertu ± THP DESTINY-Breast11 Dato-DXd + Imfinzi TROPION- Breast04 Early Low Adjuvant NST➜ residual disease Enhertu DESTINY-Breast05 Good outcomes with current SoC CTX → camizestrant (+ CDK4/6i) CAMBRIA-2 CTXAI (± CDK4/6i) 2-5 yrs → camizestrant CAMBRIA-1 NST → residual disease → Dato-DXd ± Imfinzi TROPION-Breast03 CTX → Lynparza OlympiA RECRURENCE ESR1m 1st line 125k Enhertu ± pertuzumab DESTINY-Breast09 camizestrant + CDK4/6i SERENA-4 Al + CDK4/6i → camizestrant + CDK4/6i SERENA-6 capivasertib + Faslodex + CDK4/6i CAPItello292 PD-L1- 60% capivasertib + paclitaxel CAPItello290 40% PD-L1+ Dato-DXd + Imfinzi TROPION-Breast05 Dato-DXd TROPION-Breast02 Metastatic 2nd line 90k Enhertu DESTINY-Breast03 capivasertib + Faslodex CAPItello291 HER2- Low Enhertu DESTINY-Breast06 HER2-low IHC 0-1+, 1+, 2+ Lynparza OlympiAD APPENDIX | Oncology tumour maps 3rd line 65k 4th line + 55k Enhertu DESTINY-Breast02 Dato-DXd TROPION-Breast01 Enhertu DESTINY-Breast04 HER2-low IHC 1+, 2+ All numbers are approximate. Illustrative settings and populations, not to scale. 1/2/3/4L = 1st/2nd/3rd/4th-line; est epi (G7) = estimated epidemiology across G7 (US, EU5, JP for drug treated patients. HER2 = human epidermal growth factor receptor 2; THP = docetaxel, trastuzumab, and pertuzumab; NST = neoadjuvant systemic treatment; HR = hormone receptor; SoC = standard of care; CTx = chemotherapy; Al = aromatase inhibitor; CDK4/6i = cyclin-dependent kinase 4 and 6 inhibitor; yrs = years; ESR1m = estrogen receptor 1 gene mutation; Dato-DXd = datopotamab deruxtecan; 36 TNBC = triple negative breast cancer; PD-L1 = programmed cell death ligand 1; gBRCAm = germline BRCA-mutated. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Merck & Co., Inc. (Lynparza). B#37AstraZeneca in Breast Cancer Ambition to eliminate breast cancer as a cause of death Est. epi (G7) Low risk HR-positive Intermediate / high risk HR-positive Neoadjuvant Potential for ADCs to replace chemo Early 405k Adjuvant Current SoC drives good outcomes for patients with low risk HR-positive eBC Low unmet need and limited opportunity to add benefit Camizestrant to replace ET CTX → camizestrant (+/- CDK4/6i) CAMBRIA-2 CTX → AI (+/- CDK4/6i) 2-5 yrs → camizestrant CAMBRIA-1 CRURENCE RECRU ET benefit from HR+ mBC Less 1st line 80k Camizestrant to replace ET ESR1m camizestrant + CDK4/6i SERENA-4 AI + CDK4/6i → camizestrant + CDK4/6i SERENA-6 Improve upon CDK4/6i + ET capivasertib + Faslodex + CDK4/6i CAPItello292 current ET Loss of clinical benefit to 1 1 2nd line 65k Metastatic Address ET + CDK4/6i resistance capivasertib + Faslodex CAPItello291 Replace chemotherapy APPENDIX | Oncology tumour maps Enhertu DESTINY-Breast06 HER2-low 0-1+, 1+, 2+ 3rd line 55k Loss of clinical benefit to current ET 4th line + 50k Replace chemotherapy Dato-DXd TROPION-Breast01 Replace chemotherapy Enhertu DESTINY-Breast04 HER2-low 1+, 2+ All numbers are approximate. Illustrative settings and populations, not to scale. HR = hormone receptor; est epi (G7) = estimated epidemiology across G7 (US, EU5, JP for drug treated patients; SoC = standard of care; ADC = antibody drug conjugate; ET = endocrine therapy; CTx = chemotherapy; Al = aromatase inhibitor; CDK4/6i = cyclin- 37 dependent kinase 4 and 6 inhibitor; yrs = years; ESR1m = estrogen receptor 1 gene mutation; ER = estrogen receptor; Dato-DXd = datopotamab deruxtecan. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd). 4#38Emerging Markets -9M 2023 Total Revenue +10% at CER to $9.2bn, +20% at CER ex-COVID-19 medicines Total Revenue ($m) 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 0 Q3 2021 Q4 Q1 China Emerging Markets ex-China COVID-19 medicines 38 Growth at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. CER = constant exchange rates; EM = Emerging Markets. Q2 2022 Q3 Q4 |||| Q1 APPENDIX | Emerging Markets Q2 2023 Q3 3#39Oncology Total Revenue ($m) 1,600 1,400 1,200 1,000 800 600 400 200 ☐EM 0 EROW ■ Europe ■US Q3. 315 232 259 441 Tagrisso 10% growth at CER to $4,380m in 9M 2023 2021 Q4 325 245 258 486 Q1 406 207 252 439 Q2 400 231 256 513 2022 Q3 406 203 268 521 Q4 356 206 245 535 39 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. CER = constant exchange rates; EM = Emerging Markets; EROW = Established Rest of World. Q1 444 202 257 521 Q2 2023 408 218 284 581 Q3 409 198 281 577 Total Revenue ($m) 1,200 1,000 800 600 400 200 0 ☐EM ☐EROW Europe ■US Q3 78 101 120 319 Imfinzi and Imjudo 56% growth at CER to $3,102m in 9M 2023 2021 Q4 65 101 138 330 Q1 58 101 125 315 Q2 75 104 142 374 2022 Q3 APPENDIX | 9M 2023 Product Performance 90 99 135 413 Q4 63 97 142 450 01 81 134 163 522 Q2 2023 102 222 176 576 Q3 87 221 208 610#40Oncology Product Sales ($m) 800 700 600 500 400 300 200 100 0 ■EM ☐EROW ■ Europe ■US Q3 96 67 155 270 Lynparza 3% decrease at CER to $2,070m in 9M 2023 2021 Q4 103 71 161 294 Q1 121 66 160 270 Q2 120 72 169 312 2022 Q3 117 64 164 314 Q4 130 66 162 331 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 40jj5 CER = constant exchange rates; EM = Emerging Markets; EROW = Established Rest of World. Collaboration partners: Merck & Co., Inc. (Lynparza). Q1 137 68 178 268 Q2 2023 142 77 187 311 Q3 131 71 178 322 Lynparza Collaboration Revenue: $3.8bn recorded cumulative, $3.9bn future potential Collaboration Revenue ($m) 600 400 200 0 Sales Milestone I Regulatory Milestone Q4 2021 400 Q1 175 Q2 2022 Q3 APPENDIX | 9M 2023 Product Performance 75 Q4 105 Q1 Q2 2023 Q3 3#41Oncology Total Revenue ($m) 700 600 500 400 300 200 100 ■EM EROW Europe ■US Q3 5 4 37 308 Calquence 26% growth at CER to $1,839m in 9M 2023 2021 Q4 8 8 43 336 Q1 7 13 55 339 Q2 8 18 67 396 2022 Q3 12 18 79 457 Q4 17 20 86 465 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 41 CER = constant exchange rates; EM = Emerging Markets; EROW= Established Rest of World. Collaboration partners: Daiichi Sankyo (Enhertu). Q1 18 22 108 384 Q2 2023 24 27 117 485 Q3 28 30 128 468 Total Revenue ($m) 400 350 300 250 200 150 100 50 ☐EM 0 EROW ■ Europe ■US Q3 4 9 45 Enhertu >2x growth at CER to $919m in 9M 2023 2021 Q4 5 13 49 Q1 9 1 20 57 Q2 17 2 26 73 2022 Q3 APPENDIX | 9M 2023 Product Performance 25 2 31 124 Q4 29 3 33 151 Q1 38 3 55 161 Q2 2023 69 5 70 178 Q3 72 9 79 179#42BioPharmaceuticals: Cardiovascular, Renal & Metabolism Total Revenue ($m) Farxiga 41% growth at CER to $4,389m in 9M 2023 1,800 1,600 1,400 1,200 1,000 800 600 400 200 ■EM Q3 U Q4 Q1 Q2 2021 Q3 2022 Q4 Q2 2023 441 498 578 579 72 138 136 105 393 456 506 296 339 366 320 318 391 63 78 99 423 410 98 84 EROW ■ Europe 213 225 318 309 329 342 202 228 193 275 279 323 US Q1 Q3 Total Revenue ($m) 42 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. CER = constant exchange rates; EM = Emerging Markets; EROW = Established Rest of World. 400 350 300 250 200 150 100 50 ■ EM 0 EROW ■ Europe ■ US Brilinta Stable at CER at $996m in 9M 2023 Q3 Q4 2021 Q1 Q2 Q3 Q4 2022 Q1 76 71 69 78 76 64 82 16 16 14 14 10 8 6 85 83 76 73 65 67 67 198 178 166 185 187 206 179 Q2 2023 79 6 68 178 Q3 64 6 68 193 Total Revenue ($m) 120 100 80 60 40 20 ☐EM 0 Lokelma 49% growth at CER to $300m in 9M 2023 EROW ■ Europe ■US Q3 Q4 2021 1 13. 3 32 APPENDIX | 9M 2023 Product Performance 15 5 34 Q1 3 15 6 39 Q2 Q3 Q4 2022 2 18 7 39 9 17 8 45 6 18 9 48 Q1 11 20 11 56 Q2 2023 13 13. 22 24 14 16 49 51 Q3#43BioPharmaceuticals: Respiratory & Immunology Total Revenue ($m) Fasenra 13% growth at CER to $1,134m in 9M 2023 450 400 350 300 250 200 150 100 50 ■EM Q3 Q4 Q1 2021 7 7 5 41 43 37 75 75 199 234 189 EROW Europe 75 US Q2 2023 10 12 13 14 14 19 36 35 35 35 36 35 78 77 76 88 89 86 230 229 257 201 267 249 Q2 Q3 Q4 Q1 2022 Q3 180 160 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 43 CER = constant exchange rates; EM = Emerging Markets; EROW= Established Rest of World. Collaboration partners: Amgen (Tezspire). 140 120 100 ■ EM 80 60 40 20 0 Breztri 73% growth at CER to $478m in 9M 2023 EROW ■ Europe ■ US Q3 Q4 2021 14 6 2 25 15 8 3 47 Q1 22 7 5 53 Q2 Q3 Q4 Q1 Q2 Q3 2023 2022 21 10 9 53 28 9 8 58 21 9 11 75 38 43 42 10 15 12 15 21 19 81 84 98 100 90 80 70 60 50 40 30 20 10 0 ☐EM Tezspire >5x growth at CER to $230m in 9M 2023 EROW ■ Europe ■US Q3 APPENDIX | 9M 2023 Product Performance Q4 Q1 2021 " 1 ! Q2 Q3 Q4 Q1 Q2 Q3 2023 2022 3 13 26 2 2 37 4 7 43 8 10 11 11 62 74#44BioPharmaceuticals: Respiratory & Immunology Total Revenue ($m) 800 700 600 500 400 300 200 100 0 EM EROW ■ Europe ■US Q3 151 96 155 274 Symbicort 1% decrease at CER to $1,842m in 9M 2023 2021 Q4 152 96 171 262 Q1 167 91 157 259 Q2 139 98 155 222 2022 Q3 169 91 133 237 Q4 133 95 137 255 44 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. CER = constant exchange rates; EM = Emerging Markets; EROW= Established Rest of World. Q1 229 79 147 233 Q2 2023 177 86 137 200 Q3 195 81 123 156 300 250 200 150 100 50 ☐EM 0 EROW ■ Europe ■US Q3 173 12 15 17 Pulmicort 10% growth at CER to $493m in 9M 2023 11 2021 Q4 193 13 23 19 Q1 164 13 18 22 Q2 72 12 17 15 2022 APPENDIX | 9M 2023 Product Performance Q3 103 12 14 16 - Q4 123 12 19 12 Q1 182 9 20 10 Q2 2023 90 11 16 7 Q3 119 11 13 5#45Rare Disease Total Revenue ($m) Soliris 15% decrease at CER to $2,429m in 9M 2023 1,200 1,000 800 600 400 200 0 Q3 Q4 Q1 Q2 2021 Q2 2023 83 115 88 86 99 124 91 74 221 216 190 179 183 184 163 591 574 523 491 448 445 420 ☐EM 53 EROW 86 Europe 199 240 ■US 460 608 Q3 2022 117 71 63 84 111 107 174 104 Q4 Q1 Q3 Total Revenue ($m) Ultomiris 58% growth at CER to $2,141m in 9M 2023 900 800 700 600 500 400 300 200 100 0 Q3 Q4 2021 4 ■EM ☐EROW 5 56 ■ Europe 69 100 73 US Q1 Q2 Q3 Q4 2022 24 6 4 70 72 77 105 120 122 167 214 220 236 315 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 45 Q3 2021 Total Revenue shows the numbers reported by AstraZeneca following the acquisition of Alexion, which completed on 21 July 2021. CER = constant exchange rates; EM = Emerging Markets; EROW = Established Rest of World. Q1 4 13 90 98 134 159 381 365 Q2 2023 17 17 110 131 152 184 434 445 Q3 Total Revenue ($m) 350 300 250 200 150 100 50 0 Strensiq 24% growth at CER to $847m in 9M 2023 Q3 Q4 2021 APPENDIX | 9M 2023 Product Performance ☐EM 4 6 ☐EROW 15 20 ■ Europe 16 20 US 124 173 Q1 Q2 Q3 Q4 Q1 Q2 2023 2022 9 8 9 19 19 19 19 21 18 161 193 192 10 15 9 19 21 19 21 224 205 22 21 248 Q3 5 21 22 237